



NCCN Drugs & Biologics Compendium (NCCN Compendium®)

Access to the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for non-commercial users is available via subscription.

Prior to accessing the NCCN Compendium®, users must accept an End-User License Agreement (EULA) and create a free account or login with an existing account on NCCN.org.

About the NCCN Compendium®

Based directly on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Compendium contains authoritative, scientifically derived information designed to support decision-making about the appropriate use of drugs and biologics in patients with cancer.

The recommendations for appropriate use of drugs and biologics contained in the NCCN Compendium are extracted directly from the relevant NCCN Guidelines® along with their clinical context, route of administration, recommended use, and NCCN category of evidence.

The uses identified are based upon evaluation of evidence from scientific literature integrated with expert judgment in an evidence-based process. Indicated uses are categorized in a systematic approach that describes the type of evidence available for and the degree of consensus underlying each recommendation.

All recommendations (at all category levels) in the NCCN Compendium constitute appropriate, medically-necessary care. The NCCN Compendium lists both FDA-approved uses and appropriate uses beyond the FDA-approved label.

The NCCN Compendium is accessible through an easy-to-use web-based user interface and includes a full complement of drugs and biologics recommendations found in the currently published Guidelines. The NCCN Compendium is reviewed on a continual basis to ensure that the recommendations reflect the current version of the NCCN Guidelines.

Creating the NCCN Compendium

NCCN oncology pharmacists generate the NCCN Compendium at the agent level rather than regimen; however, these agents reflect the components of regimens used in disease management. Regimen-level information is available and searchable in a separate column. In addition to Guidelines specific indication and use, NCCN adds relevant information such as pharmacologic class, relevant ICD-10 codes, and FDA indications to the searchable database. Compendium development and maintenance is accomplished by disease type and reviewed by members of the relevant NCCN panel before publication.

How the NCCN Compendium is used

The NCCN Compendium is recognized by public and private insurers alike, including, but not limited to the Centers for Medicare and Medicaid Services (CMS) and UnitedHealthcare as an authoritative reference for oncology coverage policy.

Managed care medical directors, pharmacy benefits directors, and other health care professionals also reference the NCCN Compendium when making decisions that impact patient access to appropriate therapy.

[NCCN.org/drug-compendium](https://www.nccn.org/drug-compendium)

1 The top menu of the NCCN Compendium contains various drop-down lists for displaying the database.

NCCN National Comprehensive Cancer Network® **NCCN Drugs & Biologics Compendium®**

For personal use only. Not approved for distribution.
The NCCN Drugs & Biologics Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved.
About the NCCN Drugs & Biologics Compendium®

Options

Use the drop-down menus to search the database:

Guideline: -- Select a NCCN Guideline --

Disease: -- Select a Disease Setting --

Agent: -- Select an Agent --

Brand: -- Select a Brand --

Chemotherapy Order Templates: -- Select a Chemotherapy Order Template --

Route: -- Select a Route --

Histology: -- Select a Histology --

Category of Evidence: -- Select a Category --

ICD-10: -- Select an ICD-10 Code --

Billing Code: -- Select a Billing Code --

[No Longer Recommended Uses](#)

[Transparency: Process and Recommendations](#)

[View the NCCN Compendium User Guide](#)

[Reset Filters](#) [Print](#) 0 Ready to Print

Filters: Select a Guideline

Default Sort Showing 0 to 0 of 0 entries Search:

<input type="checkbox"/>	Guideline - Disease	Agent	Brand	Pharmacologic Class	Histology	Route(s)	ICD-10 Codes	NCCN Recommended Use	NCCN Category	Chemotherapy Order Templates	FDA Indication	Billing Code
--------------------------	---------------------	-------	-------	---------------------	-----------	----------	--------------	----------------------	---------------	------------------------------	----------------	--------------

...downs are empty please click the Reset Filters button to get the latest versions

▲
An easy-to-read view of the selected compendium entries can be made available for printing or saving as a PDF by checking the box in the left most column.

2 To display the content of your choice, select any item from the drop-down menus. You can also start typing into the free-text field of each drop-down menu to narrow down your search results. You can start with any of the menus and choose from the available options in one or multiple lists.

NCCN National Comprehensive Cancer Network® NCCN Drugs & Biologics Compendium®

Options

Use the drop-down menus to search the database:

Guideline: -- Select a NCCN Guideline --

Disease: Breast Cancer Risk Reduction v.1.2024

Agent: Breast Cancer v.1.2024

Brand: Cancer-Associated Venous Thromboembolic Disease v.2.2023
Castlemann Disease v.1.2024

Chemotherapy Order Templates: Central Nervous System Cancers v.1.2023

Route: Cervical Cancer v.1.2024

NCCN National Comprehensive Cancer Network® NCCN Drugs & Biologics Compendium®

Options

Use the drop-down menus to search the database:

Guideline: Breast Cancer v.1.2024

Disease: -- Select a Disease Setting --

Agent: -- Select a Disease Setting --

Brand: Breast Cancer - Ductal Carcinoma in situ (DCIS)
Breast Cancer - Invasive Breast Cancer

Chemotherapy Order Templates: Breast Cancer - Special consideration: Breast Cancer During Pregnancy
Breast Cancer - Special consideration: Inflammatory Breast Cancer

Route: -- Select a Brand --

If you continue to filter the database using additional drop-down menus, they will automatically adjust to narrow down the available options based on each of your previous selections.

NCCN National Comprehensive Cancer Network® NCCN Drugs & Biologics Compendium®

Options

Use the drop-down menus to search the database:

Guideline: Breast Cancer v.1.2024

Disease: Breast Cancer - Invasive Breast Cancer

Agent: -- Select an Agent --

Brand: -- Select an Agent --

Chemotherapy Order Templates: Abemaciclib
Ado-trastuzumab emtansine

Route: Alpelisib
Anastrozole
Capecitabine
Cachivasetib

Histology: -- Select a Brand --

NCCN National Comprehensive Cancer Network® NCCN Drugs & Biologics Compendium®

Options

Use the drop-down menus to search the database:

Guideline: Breast Cancer v.1.2024

Disease: Breast Cancer - Invasive Breast Cancer

Agent: Facitaxel, albumin bound

Brand: -- Select a Brand --

Chemotherapy Order Templates: -- Select a Brand --

Route: Abraxane®

3 The data table will display default data fields, including: Guideline, Disease, Agent, Brand, Pharmacologic Class, Histology, Route(s), ICD-10 Codes, Billing Code, NCCN Recommended Use, NCCN Category of Evidence, Chemotherapy Order Template(s), and FDA approved indication(s).

The Guideline hyperlink will lead to the front page of the NCCN Guidelines where users can navigate to the appropriate page.

The Brand name hyperlink will lead to the most recent prescribing information (also known as the label or package insert) posted on the FDA website.

The Panel Disclosure hyperlink will lead to the list of current panel members and their most recent disclosure(s) for the associated NCCN Guidelines.

The full name of the regimen is displayed after the template ID. Click on the hyperlink to view the chemotherapy order template associated with the compendium entry.

Hovering over the NCCN Category will display more information about what each category represents. Compendium entries may contain multiple recommendations that each correspond to different categories of evidence.

NCCN Drugs & Biologics Compendium®

For personal use only. Not approved for distribution. The NCCN Drugs & Biologics Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. About the NCCN Drugs & Biologics Compendium®

Search:

Guideline: Cervical Cancer v.1.2024
 Disease: Cervical Cancer
 Agent: Paclitaxel, albumin bound
 Brand: Abraxane®
 Chemotherapy Order Templates: -- Select a Chemotherapy Order Template --

Category of Evidence: -- Select a Category --
 ICD-10: -- Select an ICD-10 Code --
 Billing Code: -- Select a Billing Code --

No Longer Recommended Uses
 Transparency: Process and Recommendations
 View the NCCN Compendium User Guide

Agent	Brand	Pharmacologic Class	Histology	Route(s)	ICD-10 Codes	NCCN Recommended Use	NCCN Category	Chemotherapy Order Templates	FDA Indication	Billing Code	
Cervical Cancer - Cervical Cancer	Paclitaxel, albumin bound	Abraxane®	Microtubule Inhibitor	Adenocarcinoma, Adenosquamous, Small cell neuroendocrine carcinoma of the cervix	IV	C53.0, C53.1, C53.8, C53.9	Second-line or subsequent therapy as a single agent for <ul style="list-style-type: none"> local/regional recurrence stage IVB or recurrence with distant metastases persistent, recurrent, or metastatic small cell neuroendocrine carcinoma of the cervix (NECC) 	2A	CRV28 Albumin-bound PAClitaxel	Metastatic Breast Cancer: Albumin-bound paclitaxel is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Non-Small Cell Lung Cancer: Albumin-bound paclitaxel is indicated for the...	J9258, J9259, J9264

Filters: Cervical Cancer v.1.2024 > Cervical Cancer > Paclitaxel, albumin bound > Abraxane®

Showing 1 to 1 of 1 entries


Guideline - Disease	Agent	Brand	Pharmacologic Class	Histology	Route(s)	ICD-10 Codes	NCCN Recommended Use	NCCN Category	Chemotherapy Order Templates	FDA Indication	Billing Code
Cervical Cancer - Cervical Cancer	Paclitaxel, albumin bound	Abraxane®	Microtubule Inhibitor	Adenocarcinoma, Adenosquamous, Small cell neuroendocrine carcinoma of the cervix (NECC), Squamous cell carcinoma	IV	C53.0, C53.1, C53.8, C53.9	Second-line or subsequent therapy as a single agent for <ul style="list-style-type: none"> local/regional recurrence stage IVB or recurrence with distant metastases persistent, recurrent, or metastatic small cell neuroendocrine carcinoma of the cervix (NECC) 	2A	CRV28 Albumin-bound PACLitaxel	Metastatic Breast Cancer: Albumin-bound paclitaxel is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Non-Small Cell Lung Cancer: Albumin-bound paclitaxel is indicated for the... read more...	J9258, J9259, J9264

4

The NCCN Compendium is built on a responsive platform that can be viewed on mobile devices. If the screen size cannot accommodate all data fields simultaneously, the interface will automatically hide certain fields and indicate this with a red numbered icon in the left most column of the data table.

Filters: Cervical Cancer v.1.2024 > Paclitaxel, albumin bound

Default Sort Showing 1 to 1 of 1 entries Search:

	Guideline - Disease	Agent	Brand	Pharmacologic Class	Histology	Route(s)	ICD-10 Codes	NCCN Recommended Use	NCCN Category	Chemotherapy Order Templates
	Cervical Cancer - Cervical Cancer <input type="checkbox"/> Guideline Panel	Paclitaxel, albumin bound	Abraxane®	Microtubule Inhibitor	Adenocarcinoma, Adenosquamous, Small cell neuroendocrine carcinoma of the cervix (NECC), Squamous cell carcinoma	IV	C53.0, C53.1, C53.8, C53.9	Second-line or subsequent therapy as a single agent for <ul style="list-style-type: none"> local/regional recurrence stage IVB or recurrence with distant metastases persistent, recurrent, or metastatic small cell neuroendocrine carcinoma of the cervix (NECC) 	2A	CRV28 Albumin-bound PACLitaxel

▲
 A red numbered icon indicates hidden fields when viewed on mobile devices, tablets, or reduced screen sizes. Click on the icon to view additional fields in a vertical display.

5

With the desired content displayed, individual or multiple records may be selected for printing by checking the printer icon box (left-most data field).

Printer icon

Reset Filters



Print

1 Ready to Print

Filters: Cervical Cancer v.1.2024 > Paclitaxel, albumin bound

Default Sort

Showing 1 to 1 of 1 entries

Search:

<input type="checkbox"/>	Guideline - Disease	Agent	Brand	Pharmacologic Class	Histology	Route(s)	ICD-10 Codes	NCCN Recommended Use	NCCN Category	Chemotherapy Order Templates
<input checked="" type="checkbox"/>	Cervical Cancer - Cervical Cancer Guideline Panel Disclosure	Paclitaxel, albumin bound	Abraxane®	Microtubule Inhibitor	Adenocarcinoma, Adenosquamous, Small cell neuroendocrine carcinoma of the cervix (NECC), Squamous cell carcinoma	IV	C53.0, C53.1, C53.8, C53.9	Second-line or subsequent therapy as a single agent for <ul style="list-style-type: none"> local/regional recurrence stage IVB or recurrence with distant metastases persistent, recurrent, or metastatic small cell neuroendocrine carcinoma of the cervix (NECC) 	2A	CRV28 Albumin-bound PAClitaxel

Print Record(s)...

Prepare PDF for Download

Print the page or save the record as a PDF.

NCCN National Comprehensive Cancer Network NCCN Drugs & Biologics Compendium

For personal use only. Not approved for distribution. The NCCN Drugs & Biologics Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit: [NCCN.org/DrugsCompendium](https://www.nccn.org/DrugsCompendium)

Disease Information	
Guideline Name:	Cervical Cancer 1.2024
Disease:	Cervical Cancer
Agent:	Paclitaxel, albumin bound
FDA Indication:	Metastatic Breast Cancer: Albumin-bound paclitaxel is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Non-Small Cell Lung Cancer: Albumin-bound paclitaxel is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. Adenocarcinoma of the Pancreas: Albumin-bound paclitaxel is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine. Consult the full FDA label with particular attention to boxed warning(s).
Brand:	Abraxane®
Category of Evidence:	2A
Histology:	Squamous cell carcinoma, Adenocarcinoma, Adenosquamous, Small cell neuroendocrine carcinoma of the cervix (NECC)
Pharmacologic Class:	Microtubule Inhibitor
Route:	IV
Recommended:	Second-line or subsequent therapy as a single agent for <ul style="list-style-type: none"> local/regional recurrence stage IVB or recurrence with distant metastases persistent, recurrent, or metastatic small cell neuroendocrine carcinoma of the cervix (NECC)
ICD10:	C53.0, C53.1, C53.8, C53.9
Billing Code:	J9258, J9259, J9264

6

Information regarding No Longer Recommended Uses and the Transparency documents for each update of the NCCN Guidelines® and associated Compendium chapter(s) is available by clicking on the options at the top of the Compendium display.

The screenshot shows the search interface of the NCCN Drugs & Biologics Compendium. It features a search bar and several dropdown menus for filtering results. The search criteria include Guideline, Disease, Agent, Brand, Chemotherapy Order Templates, Route, and Histology. On the right side, there are additional filters for Category of Evidence, ICD-10, and Billing Code. Below the search filters, there are three buttons: "No Longer Recommended Uses", "Transparency: Process and Recommendations", and "View the NCCN Compendium User Guide".

Callout 1: The Transparency: Process and Recommendations page lists the NCCN Guidelines updates by version and year, panel meeting date(s), attendance, evidence reviewed during the meeting, and the outcome of any discussions and voting that took place. A link to the panel disclosures at the time of the update is also available for each transparency posting.

Callout 2: "No Longer Recommended Uses" is a list of archived compendium entries that describe drugs and biologics previously (but no longer) recommended in the associated NCCN Guidelines.